×

Drug discovery

Sentigen

http://sghl.client.shareholder.com

Sentigen Biosciences, Inc. is a biotechnology company engaged in the development and commercialization of novel bioassay systems that elucidate the underlying biology of protein-protein interactions. We are initially applying our proprietary Tango Assay System to address the ligand-mediated activation of G protein-coupled receptors (GPCRs) for pharmaceutical discovery and development.

  • 12/8/2013
  • 13
  • 0

Chlorion Pharma Inc

http://www.chlorion.com

Chlorion Pharma, Inc. is a privately-held drug discovery company advancing next-generation CNS therapeutics to the clinic. Currently, Chlorion is focused on the development of small-molecule, disease-modifying compounds for the treatment of neuropathic pain, and subsequently for the treatment of epilepsy, bipolar disease and migraine. Chlorion's head office and research and development laboratories are located in Quebec City, Canada.

  • 12/8/2013
  • 10
  • 0

Rhinopharma Ltd

http://www.rhinopharma.com

Rhinopharma Ltd is a newly formed company dedicated to finding new drug treatments for rhinitis and other respiratory diseases. In the first phase of research strategy Rhinopharma is searching for new drugs for allergic rhinitis that can be rapidly brought to clinical trial. A longer term strategic goal of the company is to develop a range of therapeutic agents based on novel polysaccharide molecules. These molecules are biological "non-stick" agents with potential applications in inflammation, cell adhesion and tissue growth. The company plans to initially commercialize one such molecule as an anti-inflammatory agent for the treatment of allergic rhinitis in a relatively easy path to market, and then progress to research and development of agents based on active fragments of heparin and related natural and synthetic compounds. The company has access to powerful new synthetic and analytical chemical techniques which it will apply to modify heparin, and related molecules, to produce novel agents for the treatment of respiratory allergies, asthma and other inflammatory diseases. In the longer term, therapeutic applications also exist for arthritis, skin and bladder diseases. As part of this strategy the company also aims to exploit anti-adhesion molecules produced by echinoderms (starfish and related organisms) as improved therapeutic agents.

  • 12/8/2013
  • 11
  • 0

Amura Limited

http://www.amura.co.uk

Amura is a structure-based drug discovery and pre-clinical development company dedicated to the invention of new technologies, innovative medicines and novel products for improving health. Amura's therapeutic focus is in the areas of osteoporosis, bone metastasis, autoimmunity (e.g. rheumatoid arthritis, osteoarthritis, psoriasis, etc.), chronic pain and malaria. Amura's AMcore scaffold is the premier chemical solution to cysteine peptidase inhibitor design. Amura products encompass its pre-clinical therapeutic programmes and intellectual property; which will be developed by strategic alliances with globally-recognised licensing partners.

  • 12/8/2013
  • 15
  • 0

Critical Outcome Technologies Inc.

http://www.criticaloutcome.com

Critical Outcome Technologies Inc. (COTI) is a biotechnology company focused on applying its computer-based technology, CHEMSAS, to identify, profile and optimize commercially viable drug candidates at the stage of preclinical drug development. In developing its technology, COTI has focused on small molecules used to treat cancer and human immunodeficiency virus (HIV). This focus has been on cancers, such as acute leukemia in adults, hormone resistant breast cancer, hormone resistant prostate cancer, small cell lung cancer and melanoma. Using CHEMSAS, the Company is developing a pipeline of 6 to10 small molecules for specific therapy targets. These libraries in various stages of development in the pipeline are targeted at small cell lung cancer, colorectal cancer, HIV integrase inhibitors, chronic and acute leukemia, and multiple sclerosis. In May 2008, COTI announced that it has amalgamated with its wholly owned subsidiary, 6441513 Canada Inc, operating as DDP Therapeutics. (Source: ARS)

  • 12/8/2013
  • 14
  • 0

Azevan Pharmaceuticals , Inc.

http://www.azevan.com

Azevan Pharmaceuticals, Inc. (Azevan or the Company) is developing novel therapeutics for the treatment of disorders of stress, mood, and behavior. The Company leverages its expertise in behavioral neurobiology with its proprietary chemistry platform targeting G-protein coupled receptors (GPCRs) to create drug candidates. Azevan's first series of clinical candidates selectively block the effects of arginine vasopressin (AVP), which is involved in the pathophysiology of various conditions including stress-related affective illness, impulsivity/inappropriate aggression, and menstrual-related disorders. The value proposition for Azevan lies in its strong preclinical pipeline, the diverse indications and significant potential markets for selective vasopressin antagonists, and the flexibility of its proprietary chemistry that allows targeting of additional high value G-protein coupled receptors.

  • 12/8/2013
  • 12
  • 0

Polyclone Bioservices

http://www.polyclonebio.com

Polyclone is a Private Limited company, registered in Bangalore, India. The company was started with funds from founders & close associates as well as a soft loan from a Public Sector Bank. Polyclone is now set to expand and welcomes small and medium sized investments to accelerate growth and to achieve targets. The Money raised, would be used for: Upgrading of Laboratory Infrastructure Patent Validation and Filing for potential Cancer drug target Marketing This is how we propose to use funds over the next couple of years: Why Invest in Polyclone Bioservices? Biotechnology has been identified as a hot investment sector; India and China are the leading destinations for discerning investors (KPMG consulting). Polyclone's team comprises of dedicated professionals headed by forward thinking management experts with a vision to create a biotechnology giant. This is reflected in the excellent rapport we have with our Customers and the track record that we have established. This combination makes Polyclone the right investment option for small to medium sized investors who are looking for a high return on their investments over the next 2-3 years.

  • 12/8/2013
  • 16
  • 0

Plasticell Ltd

http://www.plasticell.co.uk

Plasticell is a privately held biotechnology company using novel cell culture and drug discovery platforms to produce regenerative small molecule drugs. Plasticell aims to develop drugs by elucidating the biochemical mechanisms that control the proliferation and differentiation of stem cells, the master cells responsible for tissue development and repair. Plasticell also forms alliances with industry partners to produce high value cell lines for drug discovery research and cell therapy applications.

  • 12/8/2013
  • 12
  • 0

Rivanna Pharmaceuticals , Inc.

http://www.rivannapharma.com

Rivanna Pharmaceuticals Inc. ("Rivanna", "RPI", or "the Company"), is a Charlottesville, Virginia-based biopharmaceutical company engaged in the discovery and development of novel small molecule therapeutics for the treatment of neurological diseases and cancer. The Company was founded in early 2004 to commercialize key discoveries of its scientific founder, Milton Brown, M.D., Ph.D., Associate Professor of Chemistry and Neurology at the University of Virginia. Based on principles first established in Dr. Brown's laboratory, Rivanna uses an integrated, single-laboratory approach to the design, synthesis, optimization, testing, and mechanism determination of novel chemical entities (NCEs). As compared with traditional pharmaceutical approaches to drug discovery, Rivanna's integrated systems biochemistry method significantly reduces the time and personnel required to generate NCEs. To date, over 600 novel compounds have been tested in animal models of disease for potential use as antiepileptics, analgesics, cancer chemotherapeutics, modulators of angiogenesis, and local and general anesthetics. Rivanna is currently seeking $5 million in a Series A financing to fund further development of its first three programs: epilepsy, analgesia, and oncology.

  • 12/8/2013
  • 12
  • 0

BioTechPlex Corporation

http://www.biotechplex.com

BioTechPlex provides enabling products for the discovery and development of respiratory and cardiac drugs as well as the evaluation of respiratory, cardiac and autonomic function. BioTechPlex's technologies address unmet needs for cell-based and small animal-based assays for target screening, validation and safety pharmacology and patient monitoring and respiratory aerosol drug delivery.

  • 12/8/2013
  • 16
  • 0

Molecumetics , Ltd.

http://www.molecumetics.com

Molecumetics is a chemistry-based drug discovery company dedicated to the identification of small-molecule drug candidates for license and development by pharmaceutical and biotechnology partners. In addition to the collaboration with Athersys Inc., Molecumetics has partnerships with Asahi Chemical Industries, Bristol-Myers Squibb Company, ChoongWae Pharma, and Pharmacia Corporation. The company is headquartered in the Seattle area.

  • 12/8/2013
  • 14
  • 0

Pharmexa

http://www.pharmexa.com

Pharmexa is a leading company in the field of active immunotherapy and vaccines for the treatment of cancer, serious chronic and infectious diseases. Pharmexa's proprietary technology platforms are broadly applicable, allowing the company to address critical targets in cancer and chronic diseases, as well as serious infectious diseases such as HIV, influenza, hepatitis and malaria. Pharmexa's leading programs are GV1001, a peptide vaccine that has entered phase III trials in pancreatic cancer and phase II trials in liver cancer, and HIV and hepatitis vaccines in phase I/II. Collaborative agreements include H. Lundbeck, Genimmune (subsidiary of Innogenetics), IDM Pharma and Bavarian Nordic. With operations in Denmark, Norway and USA, Pharmexa employs approximately 105 people and is listed on the Copenhagen Stock Exchange under the trading symbol PHARMX.

  • 12/8/2013
  • 13
  • 0

PharmAust Limited

http://www.pharmaust.com

PharmAust Limited is an Australia-based company that operates in the pharmaceutical industry. The Company is principally engaged in contract drug discovery and development. Some of its wholly owned subsidiaries include Animal Health Pharmaceuticals Pty Ltd, Epichem Pty Ltd, PharmAust Chemistry Limited, Echo Technologies (Thailand) Ltd, Echo Technologies (Hong Kong) Ltd and Echo Travel Solutions Sdn Bhd. In September 2008, the Company sold its entire interest in Commonwealth Biotechnologies Inc. to Venturepharm Laboratories Ltd.

  • 12/8/2013
  • 10
  • 0

Q-RNA , Inc.

http://www.q-rna.com

It is Q-RNA's mission to develop its novel drug target and discovery systems and use them to discover and optimize therapeutics to treat Alzheimer's disease (AD), a disorder with a large unmet medical need. With its initial focus on Alzheimer's disease, the Company will begin with a library of anti-amyloid compounds designed by a former founder of Neurochem, Inc. (NRMX) to dramatically improve on the compounds that Neurochem currently has in Phase II/III testing. In moving from a discovery to an integrated drug development company, Q-RNA believes that it can develop discovery tools and therapeutics for other amyloid or protein misfolding diseases including Parkinson's disease, type II diabetes, and possibly others. The Company's combination of best-in-class discovery/optimization tools, compound libraries, rational drug design and medicinal chemistry, will allow successful discovery of treatments that may slow down, interrupt, cure or even prevent Alzheimer's disease. It has the promise of identifying "blockbuster" category drugs with market potential in the multi-billions of dollars.

  • 12/8/2013
  • 14
  • 0

Allon Therapeutics Inc.

http://www.allontherapeutics.com

Allon Therapeutics Inc. is a Canadian clinical-stage biotechnology company developing drugs that protect against neurodegenerative conditions, such as Alzheimer's disease and mild cognitive impairment resulting from coronary artery bypass graft surgery. Allon's product pipeline includes ANDP Platform, which comprises AL-108, AL-208 and AL-408, and ANDF Platform, which comprises AL-309 and AL-209. The Company operates in one industry segment, being the development of biopharmaceutical products. Substantially all of the Company's operations and assets are located in Canada and the United States. On February 26, 2008, the Company announced results demonstrating statistically significant human efficacy of its drug AL-108 in a Phase IIa clinical trial in patients with amnestic mild cognitive impairment (aMCI), a precursor to Alzheimer’s disease (AD). (Source: ARS)

  • 12/8/2013
  • 13
  • 0

Syntopix Group plc

http://www.syntopix.com

Syntopix is a speciality pharmaceutical research and development company. We seek to identify compounds and develop products that treat dermatological conditions, principally acne and staphylococcal infections including MRSA. We are committed to improving the health and appearance of our consumers by offering safe and effective treatments of the highest quality, thereby creating value for our shareholders and employees.

  • 12/8/2013
  • 10
  • 0

Xcellsyz Ltd

http://www.xcellsyz.com

Xcellsyz is focussed on the discovery of new drugs for diabetes and obesity, using novel systems biology techniques. Its drug discovery activities exploit the company's scientific expertise and the unique power of its conditionally immortalised, human cell lines. Xcellsyz is aiming to extend its capabilities from this base through collaboration with biotechnology and pharmaceutical companies, as well as academic groups. Xcellsyz has already established partnerships with a number of the top-ten pharmaceutical companies. Xcellsyz believes the most effective way to build shareholder value from its unique approach to drug discovery is to apply that approach to its own drug discovery programmes. However, it is recognised that this approach has applications in a great many other disease areas. Therefore, Xcellsyz is actively seeking collaboration opportunities with pharmaceutical and drug discovery companies. It will also license its exceptional cell lines, cell models, assays and contract screening services. Xcellsyz's flexible partnering and licensing strategy is aimed at realising maximum value from its assets in order to drive its own drug discovery activities.

  • 12/8/2013
  • 17
  • 0

Cytopia Limited

http://www.cytopia.com.au

Cytopia Limited is an Australian biotechnology company focused on the discovery and development of drugs to treat cancer and other diseases. Cytopia conducts its research and drug development through subsidiaries based in Melbourne, Australia and San Francisco, the United States, and specializes in developing new small molecule compounds with an improved therapeutic profile for the treatment of cancer. The lead program for the Company is CYT997, a vascular disrupting agent for the treatment of various cancers, and, as of June 30, 2008, being trialled in Phase I and Phase II clinical studies. Cytopia also is building on its range of JAK inhibitors and kinase expertise, with CYT387, an oral JAK2 inhibitor focused on the treatment of myeloproliferative disorders. In May 2008, the Company announced an anti-cancer drug discovery and development collaboration with Cancer Therapeutics CRC Pty Ltd. (Source: ARS)

  • 12/8/2013
  • 13
  • 0

Affinium Pharmaceuticals Inc.

http://www.afnm.com

Affinium is a pharmaceutical company focused on the clinical development of antibacterials. Our lead development program encompasses a potent, orally available, novel antibiotic class for the treatment of antibiotic resistant staphylococcal infections. For information, please contact: Owen Roberts, CFA, Chief Financial Officer Affinium Pharmaceuticals, Inc.

  • 12/8/2013
  • 14
  • 0

Note

Not found any data